1. Home
  2. IMMP vs ATOS Comparison

IMMP vs ATOS Comparison

Compare IMMP & ATOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Immutep Limited

IMMP

Immutep Limited

SELL

Current Price

$3.36

Market Cap

31.5M

Sector

Health Care

ML Signal

SELL

Logo Atossa Therapeutics Inc.

ATOS

Atossa Therapeutics Inc.

SELL

Current Price

$1.62

Market Cap

25.9M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
IMMP
ATOS
Founded
1987
2009
Country
Australia
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
31.5M
25.9M
IPO Year
2012
2010

Fundamental Metrics

Financial Performance
Metric
IMMP
ATOS
Price
$3.36
$1.62
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
★ $19.00
AVG Volume (30 Days)
30.6K
★ 48.0K
Earning Date
09-01-2026
11-10-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
★ $1,758.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.26
$0.53
52 Week High
$5.36
$7.56

Technical Indicators

Market Signals
Indicator
IMMP
ATOS
Relative Strength Index (RSI) 49.75 28.30
Support Level $3.06 N/A
Resistance Level $3.55 $2.60
Average True Range (ATR) 0.34 0.16
MACD -0.05 -0.04
Stochastic Oscillator 41.09 5.46

Price Performance

Historical Comparison
IMMP
ATOS

About IMMP Immutep Limited

Immutep Ltd is a clinical-stage biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.

About ATOS Atossa Therapeutics Inc.

Atossa Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of proprietary medicines for oncology, with a focus on breast cancer and related conditions. The company's lead product candidate, oral (Z)-endoxifen, is a selective estrogen receptor modulator and degrader (SERM/SERD) in Phase 2 clinical development, being evaluated for the treatment and prevention of breast cancer and other indications.

Share on Social Networks: